mPDL1Nb mRNA-LNP treatment inhibits BMDM differentiation and maturation and reduces PD-L1, CD80, CD86 and CD206 expression. (IMAGE)

First Hospital of Jilin University

mPDL1Nb mRNA-LNP treatment inhibits BMDM differentiation and maturation and reduces PD-L1, CD80, CD86 and CD206 expression.

Caption

Flow cytometry analysis via an FMO strategy for the levels of CD11b+F4/80+ (A), CD11b+F4/80+CD80+ (B), CD11b+F4/80+CD86+ (C), CD11b+F4/80+CD68+ (D), CD11b+F4/80+CD206+ (E) and CD11b+F4/80+PD-L1+ (F) in BMDMs (left panel) during BMDM differentiation or maturation in the presence of Luc mRNA-LNP or mPDL1Nb mRNA-LNP with/without LPS. Quantitative analysis (right panel). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; two-tailed Student’s t-test. BMDM, bone marrow‑derived macrophage; FMO, fluorescence minus one; LPS, lipopolysaccharide; Luc mRNA‑LNP, luciferase messenger RNA lipid nanoparticle; mPDL1Nb, monomeric PD-L1 nanobody; ns, not statistically significant; PD-L1, programmed death‑ligand 1.

Credit

By Wen-Ming Chu, Li Ma, Brian Hew, et al.

Usage Restrictions

Credit must be given to the creator. Only noncommercial uses of the work are permitted.

License

CC BY-NC

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.